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A B S T R A C T
Parkinson's disease (PD) is one of the most common neurodegenerative disorders, which affects about 0.3% of the general population. As the population in the developed world ages, this creates an escalating burden on society both in economic terms and in quality of life for these patients and for the families that support them. Although currently available pharmacological or surgical treatments may significantly improve the quality of life of many patients with PD, these are symptomatic treatments that do not slow or stop the progressive course of the disease. Because motor impairments in PD largely result from loss of midbrain dopamine neurons in the substantia nigra pars compacta, PD has long been considered to be one of the most promising target diseases for cell-based therapy. Indeed, numerous clinical and preclinical studies using fetal cell transplantation have provided proof of concept that cell replacement therapy may be a viable therapeutic approach for PD. However, the use of human fetal cells as a standardized therapeutic regimen has been fraught with fundamental ethical, practical, and clinical issues, prompting scientists to explore alternative cell sources. Based on groundbreaking establishments of human embryonic stem cells and induced pluripotent stem cells, these human pluripotent stem cells have been the subject of extensive research, leading to tremendous advancement in our understanding of these novel classes of stem cells and promising great potential for regenerative medicine. In this review, we discuss the prospects and challenges of human pluripotent stem cell-based cell therapy for PD.
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, and one of the most common movement disorders. The disease, characterized by both motor and non-motor symptoms, affects about 0.3% of the general population and ∼1% of the population over the age of 60 (de Lau and Breteler, 2006) . It is projected that this number will increase with the aging of the population in developed countries, and PD is currently considered to be a pandemic (Dorsey and Bloem, 2017) . One of the hallmarks of PD is the loss of midbrain dopamine (mDA) neurons and, currently, dopamine (DA)-replacement therapy (e.g., L-dopa and/or DA agonists) is the gold standard and mainstay of medical therapy. Although pharmacological treatments can significantly improve the quality of life of many PD patients, the therapeutic window for achieving antiparkinsonian benefits without inducing unacceptable side effects, such as dyskinesia, shrinks over time in most patients (Kang and Fahn, 1988; Weiss et al., 1971) . 
